XERIS PHARMACEUTICALS INC's ticker is and the CUSIP is 98422LAA5. A total of 16 filers reported holding XERIS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,038,500 | -13.9% | 2,950,000 | 0.0% | 0.24% | -6.7% |
Q2 2023 | $3,528,817 | +40.7% | 2,950,000 | 0.0% | 0.25% | +35.3% |
Q1 2023 | $2,507,500 | -49.5% | 2,950,000 | -50.4% | 0.19% | -55.5% |
Q4 2022 | $4,968,250 | -31.3% | 5,950,000 | -25.2% | 0.42% | -24.9% |
Q3 2022 | $7,235,000 | +1.1% | 7,950,000 | 0.0% | 0.56% | +10.7% |
Q2 2022 | $7,155,000 | -23.7% | 7,950,000 | 0.0% | 0.50% | +0.6% |
Q1 2022 | $9,374,000 | -4.9% | 7,950,000 | 0.0% | 0.50% | +38.3% |
Q4 2021 | $9,858,000 | +8.7% | 7,950,000 | 0.0% | 0.36% | +2.5% |
Q3 2021 | $9,068,000 | -31.6% | 7,950,000 | -5.9% | 0.35% | -22.7% |
Q2 2021 | $13,267,000 | -9.5% | 8,450,000 | -1.7% | 0.46% | -40.9% |
Q1 2021 | $14,653,000 | +4.0% | 8,600,000 | +6.2% | 0.78% | +16.2% |
Q4 2020 | $14,094,000 | -3.1% | 8,100,000 | +8.0% | 0.67% | -37.4% |
Q3 2020 | $14,550,000 | +44.8% | 7,500,000 | -25.0% | 1.07% | +32.6% |
Q2 2020 | $10,050,000 | – | 10,000,000 | – | 0.80% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sessa Capital IM, L.P. | 7,450,000 | $13,103,000 | 0.84% |
683 Capital Management, LLC | 8,100,000 | $14,094,000 | 0.67% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 18,000,000 | $31,658,000 | 0.63% |
Saltoro Capital, LP | 250,000 | $439,000 | 0.22% |
UBS OCONNOR LLC | 2,000,000 | $3,461,000,000 | 0.07% |
LAZARD ASSET MANAGEMENT LLC | 7,875,000 | $13,836,000 | 0.02% |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 4,000,000 | $6,948,000 | 0.00% |
CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |